Compare Comcast Corporation (CMCSA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Novo Nordisk A/S — how do they compare? Comcast Corporation trades at $25.18 (market cap $91.02B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Comcast Corporation's market cap, and Comcast Corporation pays the higher dividend (5.15%). Which is the better fit depends on your goals.
| CMCSA | NVO | |
|---|---|---|
Market Cap | $91.02B | $207.85B |
Sector | Media | Health |
52-Week High | $32.50 | $63.98 |
52-Week Low | $21.92 | $35.29 |
Enterprise Value | $173.74B | $222.55B |
Dividend Yield | 5.15% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMCSA trades at $25.185, down slightly by 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The company shows strong fundamentals with a low P/E of 8.22, consistent earnings beats in recent quarters, and robust cash flow generation of $33.64 billion from operations in 2025. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff.
The outlook for CMCSA is positive, supported by attractive valuation, steady dividend payments, and growth in wireless and streaming. Key risks include competitive pressures in media and broadband, execution of the spinoff, and macroeconomic sensitivity. Analyst consensus is bullish with a $27.78 price target, implying potential upside from current levels.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
